Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

active_not_recruiting125%
completed250%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_4

Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma

NCT07034560
recruitingphase_4

The Basel BOMP-AID Randomized Trial

NCT03438526
completedphase_1

The Role of Melatonin in the Regulation of Blood Coagulation

NCT01741389
completedphase_2

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

NCT00972075

Clinical Trials (4)

Showing 4 of 4 trials
NCT07034560Phase 4

Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma

Active Not Recruiting
NCT03438526Phase 4

The Basel BOMP-AID Randomized Trial

Recruiting
NCT01741389Phase 1

The Role of Melatonin in the Regulation of Blood Coagulation

Completed
NCT00972075Phase 2

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4